Mediwound (NASDAQ: MDWD) — Perfil da empresa, notícias e dados financeiros
Mediwound develops treatments for burns and wounds, focusing on NexoBrid to advance care for burn patients and innovate wound management.
Mediwound
Mediwound (NASDAQ:MDWD) specializes in developing, manufacturing, and commercializing novel treatments for burns, wounds, and connective tissue disorders. Their focus lies significantly on NexoBrid, a proprietary product for the removal of eschar in adults with deep partial- and full-thickness thermal burns, aiming to advance the care and outcomes for burn patients. Beyond NexoBrid, the company is engaged in developing a pipeline of products intended to further innovate wound care, addressing significant unmet needs in the market. Mediwound's objectives include expanding their product offerings globally, enhancing patient care, and securing partnerships to leverage their technology platform for broadening their impact on wound management. Through rigorous research and development, Mediwound is dedicated to becoming a key player in transforming the therapeutic approach to wound care.
Resumo
Operações
Produtos e/ou serviços de Mediwound
- NexoBrid - an innovative, topically applied product that enzymatically removes eschar in patients with deep partial and full-thickness thermal burns.
- EscharEx - a bioactive therapy for debridement of chronic and hard-to-heal wounds, leveraging the same technology as NexoBrid, yet tailored for a different patient population.
- MW005 - a topical biological drug in development for the treatment of low-risk Basal Cell Carcinoma (BCC), aiming to provide a non-invasive treatment alternative.
- Contribution to BARDA (Biomedical Advanced Research and Development Authority) to support emergency preparedness by stockpiling NexoBrid for mass casualty incidents involving burns.
- Development of innovative pipeline projects focused on enzymatic debridement for various medical applications, showcasing the company's commitment to expanding the utility of its technology platform.
- Partnerships and collaborations for the distribution and further development of its leading products, aiming to expand global reach and improve patient access to advanced wound care solutions.
equipe executiva do Mediwound
- Ofer GonenChief Executive Officer
- Hani LuxenburgChief Financial Officer
- Shmulik HessCOO & Chief Commercial Officer
- Yaron MeyerExecutive VP, General Counsel & Corporate Secretary
- Ety KlingerChief Medical Officer
- Liron GalVice President of Manufacturing Science & Technology
- Barry J. WolfensonExecutive Vice President of Strategy & Corporate Development
- Robert J. SnyderSenior Vice President of Global Medical Affairs
Principais indicadores financeiros
Resultados divulgados pela Mediwound, em USD.
- Cap. de mercado
- 175,1 mi
- Receita (TTM)
- 11,9 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- -170.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 17 mi | -25,3 mi | -23,9 mi | |
| 20,2 mi | -19,4 mi | -30,2 mi | |
| 18,7 mi | -15,5 mi | -6,7 mi | |
| 26,5 mi | -7,7 mi | -19,6 mi |